Philippines CMDN vs CMDR: Notification and Registration Certificates

1. Key takeaways

The Philippines issues three device authorisations: the CMDN, or Certificate of Medical Device Notification, for Class A; the CMDR, or Certificate of Medical Device Registration, for Class B, C and D; and the CMDL, or Certificate of Medical Device Listing, for devices that are not placed on the market for sale. The CMDN is the lighter notification route. The CMDR requires a full ASEAN CSDT technical file and passes through technical evaluation. Both are lawful market access documents. The difference lies in the depth of documentation and the intensity of review, not in legal standing.

The distinction that matters commercially is timing. A notification route can be planned around a short window, while a registration route consumes a substantial part of a launch year. Choosing the wrong one does not merely waste an application fee. It restarts the clock, because a file submitted on the wrong route is returned rather than converted, and the elapsed months cannot be recovered by anything other than resubmission.

• Class A to CMDN; Class B, C and D to CMDR; non-sale uses to CMDL.
• Both CMDN and CMDR are valid market access certificates with the same five-year validity.
• Renewal must be filed within 90 days before expiry; a late renewal attracts a penalty under FC 2011-004.
• Class A initial CMDN applications have moved to the eServices portal since 10 March 2025.
• Class B, C and D applications are submitted by email, not through the portal.

2. Legal basis

AO No. 2018-0002 Section IV defines the three authorisation types in items 4, 5 and 6. The wording is explicit about which class receives which certificate, which removes most of the ambiguity that exists in markets where the route is inferred rather than stated. A separate FDA Circular supplies the abridged fast-track, and a 2025 Advisory fixes the submission channel for Class A initial applications.

The text of Section IV is worth quoting in substance rather than paraphrase, because the class boundaries are stated there. A CMDN is an authorisation issued to a medical device that complies with the notification requirements and is issued for Class A devices. A CMDR is an authorisation issued to a medical device that complies with the registration requirements and is issued for Class B, C and D devices. A CMDL is issued for devices intended for research, clinical trials, exhibition, donation and similar non-sale purposes.

3. Expert insights

Insight one: the lighter Class A route is still an approval, not a registration desk.

Many manufacturers read the word notification and conclude that a form is enough to sell. The Philippine CMDN still requires acceptance, evaluation and payment before issue, and the file is subject to an initial assessment. What genuinely differs is content. The CMDN concentrates on the device description, the declaration of conformity, the shelf-life statement, evidence from reference countries and colour images of the label. The CMDR builds on that base with a complete ASEAN CSDT technical file, risk management documentation, clinical evidence and proof of quality system certification.

Insight two: the transitional CMDN is finished, and outdated material still misleads applicants.

Between 2018 and 2024 the Philippines allowed a degree of regulatory flexibility for certain Class B, C and D devices that were not on the registerable device list, under arrangements set by the FC 2021-002 series and FC No. 2024-003 of 26 March 2024. The grace period expired on 30 September 2024. Since then, CMDN applications for unlisted Class B, C and D devices are no longer accepted and a CMDR must be filed. FDA Advisory No. 2025-0189 restates the position: the eServices portal covers Class A devices only, and CMDR applications for Class B, C and D are submitted through the designated mailbox. Any project schedule or budget built on the older assumption carries a systematic error from the outset.

Insight three: a correction to a persistent industry claim.

During verification we still find substantial Chinese-language material stating that Class B, C and D devices in the Philippines can begin with a CMDN, or that Class B can use the notification route. That statement has not been correct since 1 October 2024. The error is not harmless, because it typically appears in a timeline that assumes a few months to market access for a mid-risk device, and the actual route takes the better part of a year. Where a business case has been built on the older reading, the corrective step is to re-plan against the CMDR route rather than to look for an exception that no longer exists.

Insight four: validity and renewal rules are identical for both certificates.

A CMDN and a CMDR are both valid for five years, and renewal must be submitted within 90 days before expiry. A late renewal is penalised under FC 2011-004 with a doubled renewal fee plus a monthly surcharge. Because a Class A certificate feels administratively lighter, it is easily left out of the expiry register, yet the consequence of lapse is the same as for a registration certificate: the product loses its market access basis until the certificate is restored.

4. Practical recommendations

• Decide first whether the product is on the registerable list. For Class B, C and D products, check the FDA registerable device list under FC No. 2020-001-A and its amendments before deciding the route. List status and classification are two separate determinations and neither substitutes for the other.
• Prepare to CMDR standard even when filing Class A. If the product may later gain an indication or additional models, building the documentation on a CSDT skeleton substantially reduces the rework needed at the point of conversion to a CMDR.
• Put the submission channel into the project plan. Class A goes through the eServices portal at eservices.fda.gov.ph and Class B, C and D go by email to cdrrhr-productregistration@fda.gov.ph. The channel determines how the order of payment is obtained and how progress can be tracked, so it is a planning input rather than an administrative detail.

5. Verification checklist

• □ Confirm the product class under the AMDD rules.
• □ Confirm whether the product is an IVD or a refurbished device under Section III of AO No. 2018-0002.
• □ Confirm whether the product appears on the registerable device list, per FC No. 2020-001-A and amendments.
• □ Confirm the matching authorisation type: A to CMDN, B, C and D to CMDR.
• □ Confirm the submission channel in force: eServices portal or designated mailbox.
• □ Confirm the five-year validity and the 90-day renewal window in the expiry register.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com